• Neoprobe Corp., of Dublin, Ohio, appointed Mark Pykett president and CEO.
• Neuro-Biotech Corp., of Basel, Switzerland, named Rustern Yusupov vice president of marketing.
• Neurotune AG, of Zurich, Switzerland, said that Raimund Eckel will form the board, together with Gerhard Musshafen and Bruno Oesch. Armin W. Mader assumed the role of CEO.
• PanOptica Inc., of Mount Arlington, N.J., appointed Colin Goddard to its board.
• Pepscan Therapeutics BV, of Lelystad, the Netherlands, appointed Michiel Lodder chief business officer.
• Portola Pharmaceuticals Inc., of South San Francisco, appointed James Topper to its board.
• PTC Therapeutics Inc., of South Plainfield, N.J., appointed Robert J. Spiegel chief medical officer.
• Regulus Therapeutics Inc., of La Jolla, Calif., named Lars Karlsson vice president of immunology and fibrosis.
• Roche Group, of Nutley, N.J., added Janet Hammond as vice president of translational medicine-virology in pharmaceutical research and early development.
• Rosetta Genomics Ltd., of Philadelphia, elected Brian A. Markison to its board.
• Scynexis Inc., of Research Triangle Park, N.C., named Dennis Schmatz strategic advisor.
• Synergy Pharmaceuticals Inc., of New York, appointed Laura Barrow vice president of clinical operations.
• Tobira Therapeutics Inc., of Manalapan, N.J., named Andrew Hindman president and CEO.
• Topica Pharmaceuticals Inc., of Palo Alto, Calif., elected David E. Cohen to its board.
• Trevena Inc., of King of Prussia, Pa., appointed Arthur Fratamico chief business officer.
• Valeant Pharmaceuticals International Inc., of Mississauga, Ontario, appointed J. Michael Pearson chairman. Pearson also agreed to continue his role as CEO through February 2017.